Alessandro Di Paolo

Alessandro Di Paolo

Auto-generated profile, based on publicly available information

Alessandro Di Paolo

Department of Neurosurgery, IRCCS Neuromed, 86077 Pozzilli, Italy

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in World Neurosurgery
Verified
Journal Article
Closed access
AMAngelina Graziella Melone
Angelina Graziella Melone
ADAlessandro D'ELia
Alessandro D'ELia
FSFrancesca Santoro
Francesca Santoro
MSMaurizio Salvati
Maurizio Salvati
RDRoberto Delfini
Roberto Delfini
ASAntonio Santoro
Antonio Santoro

13 February 2009 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
Maurizio SalvatiMaurizio Salvati
Maurizio Salvati
ADAlessandro D’eLia
Alessandro D’eLia
CBChristian Brogna
Christian Brogna
AFAlessandro Frati
Alessandro Frati
Manila AntonelliManila Antonelli
Manila Antonelli
RDRoberto Delfini
Roberto Delfini

20 June 2008 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
Maurizio SalvatiMaurizio Salvati
Maurizio Salvati
ADAlessandro D’eLia
Alessandro D’eLia
GMGraziella Angelina Melone
Graziella Angelina Melone
CBChristian Brogna
Christian Brogna
AFAlessandro Frati
Alessandro Frati
RDRoberto Delfini
Roberto Delfini

1 August 2012 in Journal of Neurosurgery
Verified
Journal Article
Closed access
Maurizio SalvatiMaurizio Salvati
Maurizio Salvati
APAngelo Pichierri
Angelo Pichierri
MPManolo Piccirilli
Manolo Piccirilli
GBGiacoma Maria Floriana Brunetto
Giacoma Maria Floriana Brunetto
ADAlessandro D'ELia
Alessandro D'ELia
ASAntonio Santoro
Antonio Santoro
Object: In this paper, the authors' goal was to evaluate the prognostic value of YKL-40 expression as a prognostic factor for glioblastomas and to compare its validity to the already known MGMT. Methods: Between January 2002 and January 2007, 105 patients were treated for cerebral glioblastoma. The extent of removal was classified in 4 groups. YKL-40 expression was evaluated by a semiquantitative immunohistochemical staining scale (0, no staining; 1, mild expression; and 2, strong expression). MGMT promoter methylation status was analyzed with methylation-specific polymerase chain reaction. All patients received adjuvant radiotherapy and chemotherapy. Kaplan-Meier curves were used to analyze progression-free survival (PFS) and overall survival (OS), and to compare these parameters between the subgroups stratified by extent of surgical removal, MGMT methylation, and YKL-40 expression. The log-rank test was used to determine statistical significance. A multivariate regression analysis was applied to extent of removal, YKL-40 expression, and MGMT status to check their specific statistical power and to test the independence of the variables. Results: There were 55 men and 50 women with a mean age of 58 years. Extent of surgical removal is reported. The MGMT promoter was methylated in 48 patients and nonmethylated in 57. Analysis of YKL-40 expression is reported. The median PFS was 10.7 months (14.9 months in the gross-total removal subgroup) (p < 0.0001), and the median OS was 12.5 months (17.4 months in the gross-total removal group) (p < 0.0001). In the univariate analysis, OS was significantly correlated to the extent of resection (p < 0.0001), MGMT status (p < 0.0001), and YKL-40 (p < 0.0001). Multivariate analysis showed that all 3 factors reached statistical significance with respect to patient survival. In particular, surgical removal contributed more than the 2 other factors to the survival prediction (β = −0.6254). Interestingly, YKL-40 (β = −0.3867) contributed more than MGMT (β = −0.1705) to the predicted survival. Conclusions: The extent of removal is the most important factor influencing the OS of patients harboring glioblastomas. When biological aggressiveness is taken into account, YKL-40 expression was found to be an independent prognostic factor that predicts OS better than MGMT status.

30 January 2018 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
MSMaurizio Salvati
Maurizio Salvati
MTM. P. Tropeano
M. P. Tropeano
VMVincenza Maiola
Vincenza Maiola
LLLaura Lavalle
Laura Lavalle
CBChristian Brogna
Christian Brogna
ADAlessandro D’eLia
Alessandro D’eLia

3 April 2009 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
Maurizio SalvatiMaurizio Salvati
Maurizio Salvati
AFAnna I. Formichella
Anna I. Formichella
ADAlessandro D’elia
Alessandro D’elia
CBCristian Brogna
Cristian Brogna
AFAlessandro Frati
Alessandro Frati
ASAntonio Santoro
Antonio Santoro